Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
4.710
-0.030 (-0.63%)
Jul 30, 2026, 11:54 AM EDT - Market open
Foghorn Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 87.66 | 80.88 | 55.45 | 80.34 | 52.21 | 101.14 |
Short-Term Investments | 95.97 | 78.02 | 188.29 | 153.72 | 293.58 | 53.15 |
Cash & Short-Term Investments | 183.63 | 158.89 | 243.75 | 234.06 | 345.8 | 154.29 |
Cash Growth | -16.75% | -34.81% | 4.14% | -32.31% | 124.12% | -16.95% |
Other Current Assets | 4.43 | 4.34 | 5.85 | 6.12 | 5.6 | 5.27 |
Total Current Assets | 188.06 | 163.24 | 249.6 | 240.18 | 351.4 | 459.56 |
Net Property, Plant & Equipment | 32.1 | 32.86 | 32.61 | 42.91 | 49.4 | 56.08 |
Other Long-Term Assets | 2 | 2 | 1.78 | 2.82 | 4.09 | 4.13 |
Total Assets | 222.17 | 198.1 | 283.98 | 285.92 | 404.88 | 519.77 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 3.32 | 4.27 | 3.79 | 6.26 | 5.41 | 3.82 |
Accrued Expenses | 6.92 | 11.36 | 8.53 | 9.11 | 11 | 9.56 |
Current Portion of Leases | 1.86 | 0.92 | 9.07 | 8.52 | 5.97 | 6.99 |
Unearned Revenue | 52.3 | 43.19 | 45.61 | 34.55 | 32.82 | 28.32 |
Total Current Liabilities | 64.4 | 59.74 | 66.99 | 58.44 | 55.21 | 48.69 |
Long-Term Leases | 40.13 | 40.35 | 28.06 | 36.56 | 45.54 | 51.34 |
Other Long-Term Liabilities | 194.04 | 206.52 | 234.46 | 268.12 | 304.03 | 322.87 |
Total Long-Term Liabilities | 234.17 | 246.87 | 262.52 | 304.67 | 349.57 | 374.21 |
Total Liabilities | 298.58 | 306.6 | 329.51 | 363.11 | 404.77 | 422.9 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Additional Paid-in Capital | 576.06 | 523.94 | 512.52 | 395.2 | 377.23 | 361.13 |
Accumulated Other Comprehensive Income | -0.13 | 0.02 | 0.14 | -0.83 | -3.99 | -0.01 |
Retained Earnings | -652.34 | -632.47 | -558.18 | -471.56 | -373.14 | -264.26 |
Shareholders' Equity | -76.41 | -108.5 | -45.53 | -77.19 | 0.11 | 96.87 |
Total Liabilities & Equity | 222.17 | 198.1 | 283.98 | 285.92 | 404.88 | 519.77 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 41.99 | 41.27 | 37.13 | 45.07 | 51.51 | 58.33 |
Net Cash (Debt) | 141.64 | 117.62 | 206.62 | 188.98 | 294.29 | 95.96 |
Net Cash Growth | -23.74% | -43.07% | 9.33% | -35.78% | 206.69% | -7.53% |
Net Cash Per Share | 2.19 | 1.87 | 3.76 | 4.50 | 7.08 | 2.58 |
Book Value | -76.41 | -108.5 | -45.53 | -77.19 | 0.11 | 96.87 |
Book Value Per Share | -1.18 | -1.72 | -0.83 | -1.84 | 0.00 | 2.61 |
Tangible Book Value | -76.41 | -108.5 | -45.53 | -77.19 | 0.11 | 96.87 |
Tangible Book Value Per Share | -1.18 | -1.72 | -0.83 | -1.84 | 0.00 | 2.61 |